Table 2

Postpartial gland cryoablation outcomes

Catheter duration (days), median (IQR)6 (3–7)
PSA decrease from baseline (ng/ml), median (IQR)4.3 (2–6.2)
MRI findings
 % decrease in prostate volume from baseline, median (IQR)18.3 (0–28.0)
Max PI-RADS V.2, n (%)
 No lesions/not identified15 (48.40)
 22 (6.45)
 35 (16.13)
 47 (22.57)
 52 (6.45)
Post-treatment targeted biopsy (max GG), n (%)
 Benign15 (42.86)
 17 (20.0)
 211 (31.43)
 31 (2.86)
 41 (2.86)
Recurrence, n (%)
 In-field7 (20.00)
 Out-of-field6 (17.14)
 Ablated site10 (28.57)
 Non-ablated site3 (8.57)
Post-treatment plan, n (%)
 Active surveillance24 (68.57)
 Repeat PGC5 (14.29)
 Radical prostatectomy3 (8.57)
 Radiation treatment3 (8.57)
  • GG, grade group; PGC, prostate gland cryoablation; PI-RADS V.2, Prostate Imaging-Reporting and Data System V.2; PSA, prostate specific antigen.